The newly enhanced drug development platform will help empower innovators with the fastest development timelines
Evonik invests in start-up to improve patient recovery after open-chest surgery
Ligand expects 2022 royalties of $55 million to $60 million, material sales of $40 million to $50 million, and contract revenue of $52 million to $62 million.
Collaboration aims to evolve precision medicine with cell-specific delivery of gene therapy
The commissioned facility has a capacity of 7,000 TPA to produce various Esters (Mono Methyl Acetoacetamide, Methyl Acetoacetate, Ethyl Acetoacetate, and Ter-Butyl Acetoacetate)
With this approval, Brukinsa is now approved in 44 markets as BeiGene continues to advance its global registration, including the EU, US, and Great Britain
The construction is scheduled to begin in the third quarter of the calendar year 2022, with expected completion in early 2024
New subsidiaries to be established in Malaysia, Taiwan, Singapore, and Hong Kong
The device will facilitate the treatment of cerebral vasospasm following hemorrhagic stroke
The capex during the last nine months has been around Rs 110 crores which is all funded through internal accruals
Subscribe To Our Newsletter & Stay Updated
